EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function

Noemi Vergara, M Victoria Pendón-Ruiz de Mier, Cristian Rodelo-Haad, Gonzalo Revilla-González, Cristina Membrives, Juan M Díaz-Tocados, Julio M Martínez-Moreno, Ana I Torralbo, Carmen Herencia, María Encarnación Rodríguez-Ortiz, Rodrigo López-Baltanás, Williams G Richards und 8 weitere

Nephrology Dialysis Transplantation · 13.02.2023 · 38 (2) · 322-343

DOI: 10.1093/ndt/gfac220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 22.07.2022. Verfasst von Noemi Vergara und 19 weiteren Autor:innen. Beteiligte Einrichtung: Maimonides Institute for Biomedical Research of Cordoba, Cordoba, Spain. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, MicroRNAs. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, FEDER, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In chronic kidney disease (CKD) patients, increased levels of fibroblast growth factor 23 (FGF23) are associated with cardiovascular mortality. The relationship between FGF23 and heart hypertrophy has been documented, however, it is not known whether FGF23 has an effect on vasculature. Vascular smooth muscle cells VSMCs may exhibit different phenotypes; our hypothesis is that FGF23 favours a switch from a contractile to synthetic phenotype that may cause vascular dysfunction. Our objective was to determine whether FGF23 may directly control a change in VSMC phenotype.

Methods

This study includes in vitro, in vivo and ex vivo experiments and evaluation of patients with CKD stages 2–3 studying a relationship between FGF23 and vascular dysfunction.

Results

In vitro studies show that high levels of FGF23, by acting on its specific receptor FGFR1 and Erk1/2, causes a change in the phenotype of VSMCs from contractile to synthetic. This change is mediated by a downregulation of miR-221/222, which augments the expression of MAP3K2 and PAK1. miR-221/222 transfections recovered the contractile phenotype of VSMCs. Infusion of recombinant FGF23 to rats increased vascular wall thickness, with VSMCs showing a synthetic phenotype with a reduction of miR-221 expression. Ex-vivo studies on aortic rings demonstrate also that high FGF23 increases arterial stiffening. In CKD 2–3 patients, elevation of FGF23 was associated with increased pulse wave velocity and reduced plasma levels of miR-221/222.

Conclusion

In VSMCs, high levels of FGF23, through the downregulation of miR-221/222, causes a change to a synthetic phenotype. This change in VSMCs increases arterial stiffening and impairs vascular function, which might ultimately worsen cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicMicroRNAsRatsAnimalsMuscle, Smooth, VascularFibroblast Growth Factor-23Fibroblast Growth FactorsPulse Wave AnalysisPhenotypeMyocytes, Smooth MuscleCells, CulturedCell Proliferation

Stichwörter der Autor:innen

FGF23arterial stiffnesschronic kidney diseasemicroRNAvascular smooth muscle cells

Substanzen

Fibroblast Growth Factor-23Fibroblast Growth FactorsMicroRNAs

Autor:innen und Institutionen

  • Maimonides Institute for Biomedical Research of Cordoba, Cordoba, Spain.
  • University of Cordoba, Spain.
  • Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain.
  • Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, Madrid, Spain, and the European Uremic Toxins group.
  • Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Departemento de Fisiología Médica y Biofísica, Sevilla, Spain.
  • Amgen Inc., Thousand Oaks, CA, USA.

Förderung

  • Instituto de Salud Carlos III
  • FEDER
  • Junta de Andalucía
  • Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía

Zitieren

APA

Vergara, N., de Mier, M. V. P., Rodelo-Haad, C., Revilla-González, G., Membrives, C., Díaz-Tocados, J. M., Martínez-Moreno, J. M., Torralbo, A. I., Herencia, C., Rodríguez-Ortiz, M. E., López-Baltanás, R., Richards, W. G., Felsenfeld, A., Almadén, Y., Martin-Malo, A., Ureña, J., Santamaría, R., Soriano, S., Rodríguez, M., & Muñoz-Castañeda, J. R. (2023). The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function. Nephrology Dialysis Transplantation, 38(2), 322-343. https://doi.org/10.1093/ndt/gfac220

Vancouver

Vergara N, de Mier MVP, Rodelo-Haad C, Revilla-González G, Membrives C, Díaz-Tocados JM, et al. The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function. Nephrology Dialysis Transplantation. 2023;38(2):322-343. doi:10.1093/ndt/gfac220

BibTeX
@article{Vergara2023,
  author = {Vergara, Noemi and de Mier, M Victoria Pendón-Ruiz and Rodelo-Haad, Cristian and Revilla-González, Gonzalo and Membrives, Cristina and Díaz-Tocados, Juan M and Martínez-Moreno, Julio M and Torralbo, Ana I and Herencia, Carmen and Rodríguez-Ortiz, María Encarnación and López-Baltanás, Rodrigo and Richards, Williams G and Felsenfeld, Arnold and Almadén, Yolanda and Martin-Malo, Alejandro and Ureña, Juan and Santamaría, Rafael and Soriano, Sagrario and Rodríguez, Mariano and Muñoz-Castañeda, Juan R},
  title = {The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {2},
  pages = {322--343},
  doi = {10.1093/ndt/gfac220}
}
Kostenlos starten →